Adults with type 2 diabetes will have a new alternative to daily insulin injections now that the U.S. Food and Drug Administration (FDA) approved a new once-a-week insulin injection.

Ecnoglutide, a novel once-weekly injection for type 2 diabetes management, works as well as dulaglutide (a commonly prescribed once-a-week injection to manage diabetes) in lowering blood sugar levels, ...

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients with type 2 diabetes as a complement to diet and exercise. The FDA today ...

New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, ...

Also at AAO: GLP-1 agonist use and AMD risk, potential role in anterior ischemic optic neu ...

Add Yahoo as a preferred source to see more of our stories on Google. Weekly insulin shots can help control both Type 1 and Type 2 diabetes as well as daily injections do, a pair of clinical trials ...

W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...

Petah Tikva-based DreaMed Diabetes has just received FDA 510(k) clearance for MODI, a prescription medical application that automatically optimizes insulin dosing for adults with type 2 diabetes.

Insulin icodec, a once-weekly basal injection to treat type 1 diabetes, has the potential to be as effective in managing the condition as daily basal insulin treatments, according to new research. The ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal injections for diabetic macular edema and helps delay progression of ...

Share on Pinterest Ozempic is now available as a reformulated oral tablet for people with type 2 diabetes. Image courtesy of Novo Nordisk The GLP-1 medication Ozempic is now available in pill form for ...

The US Food and Drug Administration has approved Eli Lilly’s once-weekly basal insulin, Onswik, for adults with type ​2 diabetes, the drugmaker said on Thursday, offering patients ‌an alternative to ...